MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Inicio・Lista de Acciones・Lisata Therapeutics

L
Lisata Therapeutics

Cerrado

4.53 11.3

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.4

Máximo

4.85

Métricas clave
By Trading Economics
Empleados	26

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	11M 31M
Apertura anterior	-6.77
Cierre anterior	4.53

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 ene 2026, 23:07 UTC

Ganancias

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 ene 2026, 21:27 UTC

Ganancias

Texas Instruments 4Q Sales Rise, Profit Falls

27 ene 2026, 23:55 UTC

Charlas de Mercado

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 ene 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 ene 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 ene 2026, 23:39 UTC

Charlas de Mercado

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 ene 2026, 23:20 UTC

Ganancias

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 ene 2026, 23:20 UTC

Ganancias

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 ene 2026, 23:19 UTC

Ganancias

SK Innovation Posts Net Loss for Second Consecutive Year

27 ene 2026, 23:19 UTC

Ganancias

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 ene 2026, 23:18 UTC

Ganancias

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 ene 2026, 23:18 UTC

Ganancias

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 ene 2026, 23:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 ene 2026, 23:11 UTC

Charlas de Mercado

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 ene 2026, 23:07 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 ene 2026, 22:17 UTC

Charlas de Mercado

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 ene 2026, 22:06 UTC

Ganancias

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 ene 2026, 21:51 UTC

Ganancias

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 ene 2026, 21:43 UTC

Ganancias

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 ene 2026, 21:41 UTC

Ganancias

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 ene 2026, 21:38 UTC

Ganancias

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 ene 2026, 21:32 UTC

Ganancias

Ampol: Modest Profit From F&I International in 2025

27 ene 2026, 21:32 UTC

Ganancias

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 ene 2026, 21:31 UTC

Ganancias

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 ene 2026, 21:31 UTC

Ganancias

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 ene 2026, 21:30 UTC

Ganancias

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 ene 2026, 21:29 UTC

Ganancias

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 ene 2026, 21:29 UTC

Ganancias

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 ene 2026, 21:28 UTC

Ganancias

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Lisata Therapeutics Dist en los últimos 3 meses.

Finanzas

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.